IBEX vs RPAY

IBEX exhibits exceptional fundamental health with a Piotroski F-Score of 8/9, indicating strong financial stability and operational efficiency. The stock is currently trading at $27.49, which is essentially at its Graham Number ($27.9) and significantly below its growth-based intrinsic value of $88.79. Despite a bearish technical trend and recent insider selling by the CEO, the combination of a low P/E (9.13), high ROE (33.65%), and robust earnings growth (45.6% YoY) presents a compelling value opportunity.

RPAY exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and deteriorating operational efficiency. While the stock appears cheap on a Price-to-Book (0.69) and Forward P/E (4.41) basis, these metrics are overshadowed by a catastrophic -3320% YoY earnings collapse and a profit margin of -83.01%. Stagnant revenue growth (0.40%) and a current ratio below 1.0 (0.82) suggest significant liquidity risks and a lack of growth catalysts. Despite a bullish analyst consensus, the combination of a 0/100 technical trend and negative earnings surprises makes this a high-risk value trap.